167 related articles for article (PubMed ID: 31525271)
1. New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial.
Müller L; Jensen BP; Bachmann LM; Wong D; Wells AP
Clin Exp Ophthalmol; 2020 Jan; 48(1):24-30. PubMed ID: 31525271
[TBL] [Abstract][Full Text] [Related]
2. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
3. Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma.
Uusitalo H; Kähönen M; Ropo A; Mäenpää J; Bjärnhall G; Hedenström H; Turjanmaa V
Graefes Arch Clin Exp Ophthalmol; 2006 Nov; 244(11):1491-6. PubMed ID: 16628416
[TBL] [Abstract][Full Text] [Related]
4. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
5. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of silicone punctal plugs as adjuncts to topical pharmacotherapy of glaucoma--a pilot study. Punctal Plugs in Glaucoma Study Group.
Bartlett JD; Boan K; Corliss D; Gaddie IB
J Am Optom Assoc; 1996 Nov; 67(11):664-8. PubMed ID: 8979659
[TBL] [Abstract][Full Text] [Related]
8. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
9. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.
Dickstein K; Hapnes R; Aarsland T
Am J Ophthalmol; 2001 Nov; 132(5):626-32. PubMed ID: 11704023
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
12. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1998 Oct; 105(10):1945-51. PubMed ID: 9787368
[TBL] [Abstract][Full Text] [Related]
14. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
Goldberg I; Cunha-Vaz J; Jakobsen JE; Nordmann JP; Trost E; Sullivan EK;
J Glaucoma; 2001 Oct; 10(5):414-22. PubMed ID: 11711841
[TBL] [Abstract][Full Text] [Related]
15. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing.
Tan AY; LeVatte TL; Archibald ML; Tremblay F; Kelly ME; Chauhan BC
J Glaucoma; 2002 Apr; 11(2):134-42. PubMed ID: 11912361
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
[TBL] [Abstract][Full Text] [Related]
18. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
Schenker H; Maloney S; Liss C; Gormley G; Hartenbaum D
Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
[TBL] [Abstract][Full Text] [Related]
19. [Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma].
Schmidt KG; von Rückmann A; Becker R; Pillunat LE
Klin Monbl Augenheilkd; 1999 Dec; 215(6):361-6. PubMed ID: 10637801
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.
Nordmann JP; Rouland JF; Mertz BP
Curr Med Res Opin; 1999; 15(2):87-93. PubMed ID: 10494491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
